Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9783800 | 0.84 | ESR1 (0.44) | ESR1PLAAALPGKDM4EMEN1 | |
| SCHEMBL63262 | 0.83 | ESR1 (0.59) | ESR1PLAAALPGKDM4ELIMK2 | |
| SCHEMBL31398143 | 0.82 | MAP4K4 (0.39) | ESR1PLAAKDM4EMEN1POLB | |
| SCHEMBL15956713 | 0.81 | ESR1 (0.56) | ESR1PLAAALPGBRD4PDE6D | |
| SCHEMBL5321444 | 0.80 | ESR1 (0.62) | ESR1PLAAALPGKDM4EKMT2A | |
| SCHEMBL9783865 | 0.78 | LRRK2 (0.43) | ESR1PLAAKDM4EKDR | |
| SCHEMBL7095574 | 0.77 | ESR1 (0.68) | ESR1PLAAALPGPOLBKMT2A | |
| SCHEMBL27850097 | 0.77 | ESR1 (0.58) | ESR1PLAAALPGKDM4EKMT2A | |
| SCHEMBL2793396 | 0.77 | ESR1 (0.58) | ESR1PLAAALPGKDM4EKMT2A | |
| SCHEMBL27452733 | 0.77 | ESR1 (0.63) | ESR1PLAAALPGLIMK2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023136203-A1 | RESIN COMPOSITION, FILM, AND DISPLAY DEVICE | 住友化学株式会社 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023112650-A1 | METHOD FOR MANUFACTURING LENS | 住友化学株式会社 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022210268-A1 | RESIN COMPOSITION, FILM, AND COPOLYMER | 住友化学株式会社 | 2022-10-06 | — | — | WO | disclosed |
| WO-2019156326-A1 | SOLVENT-FREE COATING COMPOSITION | 주식회사 케이씨씨 | 2019-08-15 | — | — | WO | disclosed |
| CN-103116244-B | Hardening resin composition | 住友化学株式会社 | 2018-11-13 | — | — | CN | disclosed |
| CN-107434941-A | Resin combination and cured film | 住友化学株式会社 | 2017-12-05 | — | — | CN | disclosed |
| CN-102807778-B | Hardening resin composition | 住友化学株式会社 | 2017-11-07 | — | — | CN | disclosed |
| CN-107272331-A | Hardening resin composition and cured film | 住友化学株式会社 | 2017-10-20 | — | — | CN | disclosed |
| CN-102809897-B | Hardening resin composition | 住友化学株式会社 | 2017-03-01 | — | — | CN | disclosed |
| CN-105372937-A | Photosensitive resin composition | SUMITOMO CHEMICAL CO | 2016-03-02 | — | — | CN | disclosed |
| CN-103113805-A | Curable resin composition | SUMITOMO CHEMICAL CO | 2013-05-22 | — | — | CN | disclosed |
| CN-103116244-A | Curable resin composition | SUMITOMO CHEMICAL CO | 2013-05-22 | — | — | CN | disclosed |
| CN-103048881-A | Curable resin composition | SUMITOMO CHEMICAL CO | 2013-04-17 | — | — | CN | disclosed |
| CN-102807778-A | Curable resin composition | SUMITOMO CHEMICAL CO | 2012-12-05 | — | — | CN | disclosed |
| CN-102809897-A | Curable resin composition | SUMITOMO CHEMICAL CORP | 2012-12-05 | — | — | CN | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ESR1 908/4885PLAA 4141/4885ALPG 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.